HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Natural killer (NK) cell assay within bladder mucosa of patients bearing transitional cell carcinoma (TCC) after interferon (IFN) therapy: an immunohistochemical and ultrastructural study.

Abstract
The authors studied the number and the ultrastructural evidence of NK cell activation in the non-involved urothelium in patients with transitional cell carcinoma (TCC) of the urinary bladder, before and after transurethral resection (TUR) and interferon (IFN) therapy. Eight male patients, free of recurrence 1 year after TUR and IFN-a2b therapy, were studied. Each patient received 22 instillations of 50MU of IFN-a2b over a period of 1 year. Two specimens from the non-involved urothelium, one adjacent to and another away from the tumour, were obtained before and after therapy, for immunohistochemical and ultrastructural studies. The number of NK cells was evaluated immunohistochemically in paraffin sections with the CD57 monoclonal antibody, and their activation was detected by routine electron microscopy processing. Before treatment, few NK cells were randomly found in the lamina propria. At the end of therapy, however, their number increased and NK cells were found to infiltrate the urothelium, a finding that was not observed before treatment. The number of NK cells did not correlate with the degree of the inflammatory infiltrate of the mucosa. Moreover, the ultrastructural study revealed activation of NK cells with enhanced cytolytic activity. IFN therapy increases the number and promotes the activation of NK cells within the bladder mucosa. This finding could be of clinical significance in the prevention of tumour recurrence, given that NK cells enhance the immunological defense mechanisms of the bladder.
AuthorsK Natsis, T Toliou, P Stravoravdi, P Kirtsis, A Grekou, A Barich, E Konstantinidis, P Gigis
JournalInternational journal of clinical pharmacology research (Int J Clin Pharmacol Res) Vol. 17 Issue 1 Pg. 31-6 ( 1997) ISSN: 0251-1649 [Print] Switzerland
PMID9403351 (Publication Type: Journal Article)
Chemical References
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
Topics
  • Carcinoma, Transitional Cell (immunology, therapy, ultrastructure)
  • Combined Modality Therapy
  • Humans
  • Immunohistochemistry
  • Interferon alpha-2
  • Interferon-alpha (therapeutic use)
  • Killer Cells, Natural (immunology)
  • Lymphocyte Activation
  • Male
  • Microscopy, Electron
  • Mucous Membrane (immunology)
  • Recombinant Proteins
  • Surgical Procedures, Operative
  • Urinary Bladder (immunology, ultrastructure)
  • Urinary Bladder Neoplasms (immunology, therapy, ultrastructure)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: